JAMA Dermatology has published the results of a juvenile localized scleroderma (JLS) trial showing that mycophenolate mofetil (MMF) and methotrexate (MTX) are equally effective in treating JLS, noting low flare rates and possibly better tolerability with MMF.
Dr. John Cush RheumNow
6 months ago
Longitudinal study of 1761 US military service pre- & post-deployment. The prevalence of fibromyalgia in Males/Females was 2.%/2% (sames as civilians) but post-deploy incr to 8%/11% (P < 0.001). PTSD incr from 21% /18% to 23%/26%. PTSD predeployment lead to a 3 fold risk of FM. https://t.co/XTjuhjx0zd
Dr. John Cush RheumNow
6 months ago
Multinational retrospective review of CV risk in IIM (myositis) cohorts finds among 336 pts that > 1/3 are at moderate-high risk for CVD - but 34 % prescribed a statin. Moderate-high risk scores seen w/ necrotizing myopathy (OR 4.6), steroids (OR 1.8), dyslipidaemia (1.2) https://t.co/4IMiaHJvL3
Dr. John Cush RheumNow
6 months ago
DARWIN study ADHD med use among children and adults in Europe (Belgium, Germany, Netherlands, Spain, UK) more than doubled betw 2010 to 2023. IN UK use went up 20X in females, 15X males. (Ed. note: ADHD meds-->poor sleep-->fibromyalgia-->MSK pains) https://t.co/KlvUF1vhhj https://t.co/yEWXwM0WBL
Dr. John Cush RheumNow
6 months ago
Clinical contributors to pathogenesis and treatment outcomes for rheumatoid arthritis. Full read review of pathogenesis and unmet needs in #RA https://t.co/OZxOuXdnIq https://t.co/LuYoLVfb7N
The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.
Dr. John Cush RheumNow
6 months ago
Lupus Foundation announced today that US House of Representatives have approved $27 Million in Funding for Lupus Programs in 2026 w/ fund available from (CDC), OMH, & DoD. Funding increased 40% @ CDC, 33% @OMH, & $415 million @ National Institutes of Health https://t.co/ENcykcW7yA
Dr. John Cush RheumNow
6 months ago
Roche Canada announced that Health Canada has approved obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Following four initial doses in the first year, Gazyva can be administered twice yearly https://t.co/snAVErShjK
Dr. John Cush RheumNow
6 months ago
Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa
A coalition of leading international experts have released the first comprehensive Consensus Statement on the Management of Vertebral Fractures in Chronic Kidney Disease (CKD) Stages G4–G5D. The statement highlights a neglected yet devastating complication of advanced kidney disease: skeletal fragility and vertebral fractures.
Dr. John Cush RheumNow
6 months ago
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?
Dr. John Cush RheumNow
6 months ago
Emergencies, Independence & Hemorrhage (1.23.2026)
Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.
https://t.co/l4iMADwA1A https://t.co/YB4mnb8Xlu
Dr. John Cush RheumNow
6 months ago
Testing for RF, CCP, ESR and CRP
Check out the accompanying Advanced Practice Rheum: Rheumatoid and Inflammation Testing video.
https://t.co/o1sle6CKg5 https://t.co/roYXcbPdBh
Dr. John Cush RheumNow
6 months ago
Advanced Practice Rheum: Methotrexate
https://t.co/PHAFWBG4gJ https://t.co/p9cMqT4nhR
A 5 year JAMA study shows that a treat-to-target (serum urate < 6 mg/dL) study finds that effective urate-lowering treatment (ULT) results in a significantly reduced cardiovascular risk in patients with gout.
